FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313890710> ?p ?o ?g. }

• W4313890710 endingPage "63" @default.
• W4313890710 startingPage "51" @default.
• W4313890710 abstract "Myelodysplastic syndromes (MDS) are heterogeneous group of clonal hematopoietic stem cell neoplasms that have limited approved treatment options. Multiple novel agents are currently being tested in a clinical trial setting. From a therapeutic perspective, MDS is generally divided into lower-risk and higher-risk disease. In this review, we summarize some of the most prominent novel agents currently in development.This review focuses on select clinical trials in both lower- and higher-risk MDS, elucidating the mechanisms of action and rationale for drug combinations and summarizing early safety and efficacy data using novel agents in MDS.Advances in understanding the innate immune system, telomere biology, as well as genomic drivers of the disease have led to the development of multiple novel agents that are currently in late stages of clinical development in MDS. Imetelstat is being tested in lower-risk disease and the phase III clinical trial recently completed accrual. Magrolimab, sabatolimab, and venetoclax in addition to novel oral hypomethylating agents (HMA) are being investigated in higher-risk MDS. These advances will hopefully bring better treatment options to patients and lead to a shift in the treatment paradigm. Post HMA therapy remains an area of dire unmet need.MDS are rare bone marrow cancers that lead to low blood counts and carry the risk of disease progression to acute myeloid leukemia. The disease risk (lower vs higher) determines the treatment approach. For lower-risk MDS, the focus has been to improve blood counts and patients’ quality of life. Novel treatment strategies are moving earlier in the course of disease to perhaps delay progression. In higher-risk MDS, the goal is to prolong survival and delay progression to acute leukemia. Multiple advanced-phase clinical trials are ongoing to evaluate agents in combination with azacitidine that have shown encouraging results in earlier-phase studies." @default.
• W4313890710 created "2023-01-10" @default.
• W4313890710 creator A5048791112 @default.
• W4313890710 creator A5067521829 @default.
• W4313890710 creator A5090985347 @default.
• W4313890710 date "2023-01-02" @default.
• W4313890710 modified "2023-09-24" @default.
• W4313890710 title "Advances in myelodysplastic syndromes: promising novel agents and combination strategies" @default.
• W4313890710 cites W1541533982 @default.
• W4313890710 cites W1602160610 @default.
• W4313890710 cites W187238933 @default.
• W4313890710 cites W1973018894 @default.
• W4313890710 cites W1994881231 @default.
• W4313890710 cites W2000597113 @default.
• W4313890710 cites W2009650262 @default.
• W4313890710 cites W2066053804 @default.
• W4313890710 cites W2081279521 @default.
• W4313890710 cites W2096848137 @default.
• W4313890710 cites W2114492363 @default.
• W4313890710 cites W2118771330 @default.
• W4313890710 cites W2129510594 @default.
• W4313890710 cites W2168706693 @default.
• W4313890710 cites W2169007954 @default.
• W4313890710 cites W2326726820 @default.
• W4313890710 cites W2342968295 @default.
• W4313890710 cites W2423491126 @default.
• W4313890710 cites W2463012969 @default.
• W4313890710 cites W2467917196 @default.
• W4313890710 cites W2521557372 @default.
• W4313890710 cites W2547174163 @default.
• W4313890710 cites W2584597412 @default.
• W4313890710 cites W2705856695 @default.
• W4313890710 cites W2741014649 @default.
• W4313890710 cites W2742767772 @default.
• W4313890710 cites W2783500974 @default.
• W4313890710 cites W2788733333 @default.
• W4313890710 cites W2800050586 @default.
• W4313890710 cites W2804724049 @default.
• W4313890710 cites W2884238005 @default.
• W4313890710 cites W2892971505 @default.
• W4313890710 cites W2898284215 @default.
• W4313890710 cites W2900418013 @default.
• W4313890710 cites W2907462344 @default.
• W4313890710 cites W2913296480 @default.
• W4313890710 cites W2915146394 @default.
• W4313890710 cites W2919014561 @default.
• W4313890710 cites W2922692686 @default.
• W4313890710 cites W2937725692 @default.
• W4313890710 cites W2983543368 @default.
• W4313890710 cites W2984346248 @default.
• W4313890710 cites W2984372424 @default.
• W4313890710 cites W2986873684 @default.
• W4313890710 cites W2988130036 @default.
• W4313890710 cites W2989313507 @default.
• W4313890710 cites W2998901800 @default.
• W4313890710 cites W3006574094 @default.
• W4313890710 cites W3013447738 @default.
• W4313890710 cites W3015984203 @default.
• W4313890710 cites W3020865171 @default.
• W4313890710 cites W3040753837 @default.
• W4313890710 cites W3048827006 @default.
• W4313890710 cites W3089299415 @default.
• W4313890710 cites W3094836108 @default.
• W4313890710 cites W3095116203 @default.
• W4313890710 cites W3095592919 @default.
• W4313890710 cites W3096363798 @default.
• W4313890710 cites W3096853864 @default.
• W4313890710 cites W3097144642 @default.
• W4313890710 cites W3097251831 @default.
• W4313890710 cites W3108935746 @default.
• W4313890710 cites W3115703564 @default.
• W4313890710 cites W3115741078 @default.
• W4313890710 cites W3115892358 @default.
• W4313890710 cites W3119649652 @default.
• W4313890710 cites W3123615891 @default.
• W4313890710 cites W3128080784 @default.
• W4313890710 cites W3131928636 @default.
• W4313890710 cites W3133256211 @default.
• W4313890710 cites W3139163066 @default.
• W4313890710 cites W3164990782 @default.
• W4313890710 cites W3175087604 @default.
• W4313890710 cites W3176370909 @default.
• W4313890710 cites W3191218462 @default.
• W4313890710 cites W3191602849 @default.
• W4313890710 cites W3206811938 @default.
• W4313890710 cites W3207985070 @default.
• W4313890710 cites W3211403252 @default.
• W4313890710 cites W3211699349 @default.
• W4313890710 cites W3211798246 @default.
• W4313890710 cites W3212034898 @default.
• W4313890710 cites W3212328437 @default.
• W4313890710 cites W3212428411 @default.
• W4313890710 cites W3214467240 @default.
• W4313890710 cites W3214535227 @default.
• W4313890710 cites W4206917876 @default.
• W4313890710 cites W4210627757 @default.
• W4313890710 cites W4210791570 @default.
• W4313890710 cites W4210920001 @default.

• next